瘤内注射CCL21偶联穹窿纳米颗粒与胶质瘤体内模型肿瘤体积缩小相关
该初步研究在胶质母细胞瘤(GBM)小鼠侧腹模型中,将CCL21包装入穹窿纳米颗粒(CPZ-CCL21)后行瘤内注射,结果显示CPZ-CCL21组平均肿瘤体积最小,且是唯一肿瘤体积百分比变化为负的治疗组;作者认为穹窿纳米颗粒是提高药物递送与免疫应答的可行载体,后续需颅内原位模型动物研究。
要点
- 在GBM小鼠侧腹模型中,瘤内注射CPZ-CCL21与肿瘤体积缩小相关。
- CPZ-CCL21组平均肿瘤体积最小,且是唯一肿瘤体积百分比变化为负的治疗组。
- 作者认为穹窿纳米颗粒是提高药物递送与免疫应答的可行载体。
核心结论
- 这项初步研究确立穹窿纳米颗粒作为在GBM小鼠侧腹模型中提高药物递送与免疫应答的可行载体。
- 未来需要涉及颅内原位肿瘤模型的动物研究,以全面评估CPZ-CCL21作为绕过血脑屏障、增强颅内免疫活性并改善颅内肿瘤控制与生存的策略的潜力。
研究设计与样本
- 初步研究,采用GBM小鼠侧腹模型。
- 将GL261细胞皮下注射至八周龄雌性C57BL/6小鼠左侧腹。
- 小鼠接受瘤内注射以下四种处理之一:CPZ-CCL21、游离重组CCL21趋化因子空穹窿纳米颗粒、空穹窿纳米颗粒或PBS。
主要发现
- 结果显示瘤内注射CCL21包装的穹窿纳米颗粒可在体内减小肿瘤体积。
- 注射CPZ-CCL21的小鼠平均肿瘤体积最小,且是唯一肿瘤体积百分比变化为负的治疗组。
局限性
- 这是一项初步研究。
- 研究采用小鼠侧腹模型而非颅内原位肿瘤模型。
- 未来需要涉及颅内原位肿瘤模型的动物研究来全面评估其潜力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Glioblastoma (GBM) is the most common and malignant primary adult brain tumor. Current care includes surgical resection, radiation, and chemotherapy. Recent clinical trials for GBM have demonstrated extended survival using interventions such as tumor vaccines or tumor-treating fields. However, prognosis generally remains poor, with expected survival of 20 months after randomization. Chemokine-based immunotherapy utilizing CCL21 locally recruits lymphocytes and dendritic cells to enhance host antitumor response. Here, we report a preliminary study utilizing CPZ-vault nanoparticles as a vehicle to package, protect, and steadily deliver therapy to optimize CCL21 therapy in a murine flank model of GBM. METHODS: GL261 cells were subcutaneously injected into the left flank of eight-week-old female C57BL/6 mice. Mice were treated with intratumoral injections of either: (1) CCL21-packaged vault nanoparticles (CPZ-CCL21), (2) free recombinant CCL21 chemokine empty vault nanoparticles, (3) empty vault nanoparticles, or 4) PBS. RESULTS: The results of this study showed that CCL21-packaged vault nanoparticle injections can decrease the tumor volume in vivo. Additionally, this study showed mice injected with CCL21-packaged vault nanoparticle had the smallest average tumor volume and remained the only treatment group with a negative percent change in tumor volume. CONCLUSIONS: This preliminary study establishes vault nanoparticles as a feasible vehicle to increase drug delivery and immune response in a flank murine model of GBM. Future animal studies involving an intracranial orthotopic tumor model are required to fully evaluate the potential for CCL21-packaged vault nanoparticles as a strategy to bypass the blood brain barrier, enhance intracranial immune activity, and improve intracranial tumor control and survival.
引用
- Voth BL, Pelargos PE, Barnette NE, et al. Intratumor injection of CCL21-coupled vault nanoparticles is associated with reduction in tumor volume in an in vivo model of glioma. J Neurooncol. 2020. PMID: 32274629. doi:10.1007/s11060-020-03479-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。